Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Daniel C Pevear"'
Autor:
Kimberly F. Glassman, Joan S. Brugge, Anthony F. Purchio, Laura T. Kakach, Thomas R. Fuerst, Robert M. Woods, C. Kendall Stover, Srinivas K. Chunduru, Jeffrey R. Hincks, Mark A. McKinlay, Claude H. Nash, Daniel C. Pevear, Thomas P. Monath, Charles M. Rice, Pam Peters
Publikováno v:
Journal of Virology. 97
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::289fa550ab7b1d0ee8e72c0518bea25d
https://doi.org/10.1128/jvi.01643-22
https://doi.org/10.1128/jvi.01643-22
Autor:
James A. Karlowsky, Meredith A. Hackel, Mark G. Wise, David A. Six, Tsuyoshi Uehara, Denis M. Daigle, Susan M. Cusick, Daniel C. Pevear, Greg Moeck, Daniel F. Sahm
Publikováno v:
Antimicrobial Agents and Chemotherapy. 67
Taniborbactam is a novel cyclic boronate β-lactamase inhibitor in clinical development in combination with cefepime. We assessed the in vitro activity of cefepime-taniborbactam and comparators against a 2018–2020 collection of Enterobacterales ( n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2db316b6652ae028b33e829665b98779
https://doi.org/10.1128/aac.01281-22
https://doi.org/10.1128/aac.01281-22
Autor:
Kimberly F, Glassman, Joan S, Brugge, Anthony F, Purchio, Laura T, Kakach, Thomas R, Fuerst, Robert M, Woods, C Kendall, Stover, Srinivas K, Chunduru, Jeffrey R, Hincks, Mark A, McKinlay, Claude H, Nash, Daniel C, Pevear, Thomas P, Monath, Charles M, Rice, Pam, Peters
Publikováno v:
J Virol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::50aa62bbb8ebc5d3e7f4554a05792041
https://pubmed.ncbi.nlm.nih.gov/36468860
https://pubmed.ncbi.nlm.nih.gov/36468860
Publikováno v:
Open Forum Infectious Diseases. 9
Background Cefepime-taniborbactam (FTB) combines cefepime (FEP), a fourth generation cephalosporin with taniborbactam, a novel inhibitor of metallo (MBL)- and serine β-lactamases (SBL). FTB 2.5g IV q8h was safe and effective in adults with complicat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef15fc50becb9f0f890c59c9c0e9fa2d
https://doi.org/10.1093/ofid/ofac492.642
https://doi.org/10.1093/ofid/ofac492.642
Autor:
James A. Karlowsky, Mark G. Wise, Meredith A. Hackel, Daniel C. Pevear, Greg Moeck, Daniel F. Sahm
Publikováno v:
Antimicrobial Agents and Chemotherapy. 66
Ceftibuten-ledaborbactam etzadroxil is a cephalosporin-boronate β-lactamase inhibitor prodrug combination under development as an oral treatment for complicated urinary tract infections caused by multidrug-resistant (MDR) Enterobacterales producing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73b6bc6b54bf8b87c1f6c07c78b4fa7c
https://doi.org/10.1128/aac.00934-22
https://doi.org/10.1128/aac.00934-22
Autor:
William J. Weiss, Christopher J. Burns, Randy W. Jackson, Greg Moeck, Eugen F. Mesaros, Jodie Hamrick, Susan M Cusick, Boyd Steven A, Bin Liu, Denis M. Daigle, Cassandra L Chatwin, Lisa McLaughlin, Kaitlyn John, Daniel C. Pevear, Allison L. Zulli, Robert E. Lee Trout, Luigi Xerri, Mark Pulse
Publikováno v:
Journal of Medicinal Chemistry
A major antimicrobial resistance mechanism in Gram-negative bacteria is the production of β-lactamase enzymes. The increasing emergence of β-lactamase-producing multi-drug-resistant “superbugs” has resulted in increases in costly hospital Emerg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::516a17f5ca36ebed444b8e9c579d316c
https://doi.org/10.1021/acs.jmedchem.1c00437
https://doi.org/10.1021/acs.jmedchem.1c00437
Autor:
Denis M. Daigle, Christopher J. Burns, William J. Weiss, Daniel C. Pevear, Cullen L. Myers, Kaitlyn John, Jodie Hamrick, Robert E. Lee Trout, Susan M Cusick, Mark Pulse, Luigi Xerri, Cassandra L Chatwin, Tsuyoshi Uehara, Gregory Moeck
Publikováno v:
Antimicrobial Agents and Chemotherapy. 65
There is an urgent need for oral agents to combat resistant Gram-negative pathogens. Here, we describe the characterization of VNRX-5236, a broad-spectrum boronic acid β-lactamase inhibitor (BLI), and its orally bioavailable etzadroxil prodrug, VNRX
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73fdf2a24978a9d74f4294ac27e044b7
https://doi.org/10.1128/aac.00552-21
https://doi.org/10.1128/aac.00552-21
Autor:
Bin Liu, M. Benvenuti, Christopher J. Burns, G.-H. Chu, Mcgarry Daniel G, Luigi Xerri, Denis M. Daigle, Robert E. Lee Trout, Cecilia Pozzi, Daniel C. Pevear, Stefano Mangani, William J. Weiss, Randy W. Jackson, F. De Luca, Jean Denis Docquier, Susan M Cusick, Jodie Hamrick
Publikováno v:
'Journal of Medicinal Chemistry ', vol: 63, pages: 2789-2801 (2020)
Journal of Medicinal Chemistry
Journal of Medicinal Chemistry
A major resistance mechanism in Gram-negative bacteria is the production of β-lactamase enzymes. Originally recognized for their ability to hydrolyze penicillins, emergent β-lactamases can now confer resistance to other β-lactam drugs, including b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a77265b9a9b18c42fefa458896ab4a47
https://doi.org/10.1021/acs.jmedchem.9b01518
https://doi.org/10.1021/acs.jmedchem.9b01518
Autor:
Cassandra L, Chatwin, Jodie C, Hamrick, Robert E L, Trout, Cullen L, Myers, Susan M, Cusick, William J, Weiss, Mark E, Pulse, Luigi, Xerri, Christopher J, Burns, Gregory, Moeck, Denis M, Daigle, Kaitlyn, John, Tsuyoshi, Uehara, Daniel C, Pevear
Publikováno v:
Antimicrobial Agents and Chemotherapy
There is an urgent need for oral agents to combat resistant Gram-negative pathogens. Here, we describe the characterization of VNRX-5236, a broad-spectrum boronic acid β-lactamase inhibitor (BLI), and its orally bioavailable etzadroxil prodrug, VNRX
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e1909538c2e10337186aadd9036b1b51
https://pubmed.ncbi.nlm.nih.gov/34001510
https://pubmed.ncbi.nlm.nih.gov/34001510
Autor:
Kaitlyn John, Jodie Hamrick, David A. Six, Denis M. Daigle, Tsuyoshi Uehara, Luigi Xerri, Susan M Cusick, Daniel C. Pevear, Manuela Benvenuti, Cassandra L Chatwin, Christopher J. Burns, Salvador Vernacchio, Randy W. Jackson, Greg Moeck, Bin Liu, Robert E. Lee Trout, Filomena De Luca, Jean Denis Docquier, Stefano Mangani, Cullen L. Myers, Cecilia Pozzi
As shifts in the epidemiology of β-lactamase-mediated resistance continue, carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA) are the most urgent threats. Although approved β-lactam (BL)-β-lactamase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ebef2baf47b65ca9a3ff1093605020a
http://hdl.handle.net/11365/1095652
http://hdl.handle.net/11365/1095652
